Navigation Links
Fibrocell Science, Inc. Names David Pernock Chief Executive Officer

EXTON, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications, announced today that David Pernock, Chairman of the Board of Directors, has been named Chief Executive Officer (CEO), effective immediately. Pernock most recently served as Senior Vice President (SVP), Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. He joined Fibrocell's Board of Directors last September.

"I'm pleased to take on the role of Fibrocell's CEO during this pivotal period for the company and our lead investigational cell therapy Laviv™ (azficel-T)(1)," said Pernock. "We are excited about the potential for this therapy as we continue to address the U.S. Food & Drug Administration's (FDA) requests as outlined in its complete response letter to our March 2009 biologics license application for Laviv's use in the treatment of moderate to severe nasolabial fold wrinkles."

Mr. Pernock takes on the role of Fibrocell Science's CEO with extensive leadership experience in healthcare sales and commercialization, building business units, partnerships, and brands at GlaxoSmithKline. During a long career at the multinational pharmaceutical company that culminated with his role as SVP, Mr. Pernock was promoted numerous times to levels of increasing responsibility including Vice President of Marketing, Pharmaceuticals; Vice President of Sales and Marketing, Oncology; Vice President of Managed Care; and, Vice President of Sales. Mr. Pernock holds a B.S. in Business Administration from Arizona State University. He is a director of Martek Biosciences Corporation and serves in many philanthropic organizations.

"David's proven history of delivering results across many varied corporate functions makes him an asset to Fibrocell Science as a CEO," said Declan Daly, Fibrocell Science, Inc. Chief Operating Officer and Chief Financial Officer.  "He has had a positive impact on the leadership team and throughout the company as Chairman, and we welcome his broader role within our organization."

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing regenerative fibroblast cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.  For additional information, please visit

Forward Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, the ability of the Company to complete the histopathology study and provide to the FDA the requested data on a timely basis. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.

(1)  The FDA is currently evaluating a proposed brand name, Laviv™.

SOURCE Fibrocell Science, Inc.



SOURCE Fibrocell Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
2. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
3. Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
4. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
5. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
6. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
7. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
8. For creating new field of science, Texas chemist wins international prize
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
11. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):